|
|
 |
KINARIS Biomedicals applies a target based rational drug design approach embracing in-silico methods, X-ray cristalography, cell biology and chemistry to identify, optimize and validate small molecules that selectively target cytoskeleton proteins, in particular members of the myosin and kinesin motor protein families. KINARIS motor proteins are new druggable targets. The company develops allosteric inhibitors and activators for the therapeutic treatment of cancer, pathogenic infections, cardiovascular and CNS-related diseases.
|
|
